1. Home
  2. TPCS vs IRD Comparison

TPCS vs IRD Comparison

Compare TPCS & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TPCS
  • IRD
  • Stock Information
  • Founded
  • TPCS 1956
  • IRD 2018
  • Country
  • TPCS United States
  • IRD United States
  • Employees
  • TPCS N/A
  • IRD N/A
  • Industry
  • TPCS Metal Fabrications
  • IRD
  • Sector
  • TPCS Industrials
  • IRD
  • Exchange
  • TPCS Nasdaq
  • IRD NYSE
  • Market Cap
  • TPCS 27.2M
  • IRD 35.7M
  • IPO Year
  • TPCS N/A
  • IRD N/A
  • Fundamental
  • Price
  • TPCS $2.73
  • IRD $0.93
  • Analyst Decision
  • TPCS
  • IRD Strong Buy
  • Analyst Count
  • TPCS 0
  • IRD 1
  • Target Price
  • TPCS N/A
  • IRD $8.00
  • AVG Volume (30 Days)
  • TPCS 49.4K
  • IRD 141.6K
  • Earning Date
  • TPCS 01-21-2025
  • IRD 03-25-2025
  • Dividend Yield
  • TPCS N/A
  • IRD N/A
  • EPS Growth
  • TPCS N/A
  • IRD N/A
  • EPS
  • TPCS N/A
  • IRD N/A
  • Revenue
  • TPCS $33,182,059.00
  • IRD $8,381,000.00
  • Revenue This Year
  • TPCS N/A
  • IRD N/A
  • Revenue Next Year
  • TPCS N/A
  • IRD $29.37
  • P/E Ratio
  • TPCS N/A
  • IRD N/A
  • Revenue Growth
  • TPCS 6.44
  • IRD N/A
  • 52 Week Low
  • TPCS $2.16
  • IRD $0.81
  • 52 Week High
  • TPCS $5.95
  • IRD $2.34
  • Technical
  • Relative Strength Index (RSI)
  • TPCS 42.59
  • IRD N/A
  • Support Level
  • TPCS $2.58
  • IRD N/A
  • Resistance Level
  • TPCS $2.93
  • IRD N/A
  • Average True Range (ATR)
  • TPCS 0.28
  • IRD 0.00
  • MACD
  • TPCS 0.00
  • IRD 0.00
  • Stochastic Oscillator
  • TPCS 67.06
  • IRD 0.00

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: